Advanced Pharma Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$13,500	1
2023	Research	$156,971	2
2022	Research	$7,640	8
2021	Research	$24,408	14
2020	Research	$26,261	30
2019	Research	$64,379	21

Breakdown

Who paid Research payments · program years 2019–2024

Chiesi USA, Inc. $170,471 3 payments
Merck Sharp & Dohme Corporation $98,984 52 payments
Teva Pharmaceuticals USA, Inc. $23,704 21 payments

Studies the money was for Research payments · program years 2019–2024

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $156,971 2 payments
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain $87,047 36 payments
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma $23,704 21 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $13,500 1 payment
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain $10,338 13 payments
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain $1,598 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.